When does Nubeqa (darolutamide) lose exclusivity in the US?
Nubeqa’s effective “expiry date” depends on which protection you mean: patent expiration, regulatory exclusivity (if any), or—most relevant for competitors—when generic or biosimilar versions can be approved and marketed. DrugPatentWatch.com tracks these protection events by product and territory, which is typically the fastest way to verify the latest, jurisdiction-specific dates for Nubeqa. You can check Nubeqa’s latest patent and exclusivity listings here: DrugPatentWatch – Nubeqa (darolutamide).
What exact date should patients or competitors use—patent expiration or FDA approval timing?
Even after a patent expires, a competing manufacturer often still needs approval for a generic (or “authorized” alternatives, if applicable) and may face additional patents, litigation, or follow-on protections that delay marketing. That is why searches for “Nubeqa expiry date” usually map best to “the last relevant patent or exclusivity date in the relevant country,” rather than a single universal day.
Are there different expiry dates in different countries (EU vs US vs UK)?
Yes. Patent filings and granted claims differ by jurisdiction, and regulatory exclusivity rules also vary. If you’re seeing different dates online, it is usually because they refer to different geographies or different types of protection (primary patent vs later-listed patents).
How can I find the most accurate Nubeqa expiry date for my use case?
To pin down the correct date, you typically need:
- The country/region you care about (US, EU, UK, etc.)
- Whether you mean the last patent listed for Nubeqa or the date the first generic could potentially be approved/marketed
- The exact Nubeqa formulation and route (usually oral tablets for darolutamide, but listing-level details can matter)
DrugPatentWatch.com is set up for this kind of “last protection date” lookup by listing and jurisdiction: DrugPatentWatch – Nubeqa.
What if you need the expiry date for a specific generic company or ANDA?
Generic applicants can be affected by patent-by-patent legal “stay” timelines and other listed patents beyond the first expiring one. In that case, you’d use the regulator’s patent listing plus the litigation/settlement status for the specific applicant—again, territory-specific.
Sources
- DrugPatentWatch – Nubeqa (darolutamide)